Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers

Fig. 1

NILK-2301 mediated killing of CEACAM5-positive tumor cell lines based on LDH release after 48 h of incubation. Data for SK-CO-1, SNU-C1, LS-174 T, H508, SW1116, MKN-45, SNU-16, H727, and H2122 are shown. No killing was observed for CEACAM5-negative cell line A549 and CCD841CoN cells, isolated from normal colon, as well as HBEpiC, isolated from normal bronchial tissue. Please refer to Additional file 1: Figure S4 for TDCC data based on ATP quantification after 72 h of incubation

Back to article page